| Identification | Back Directory | [Name]
DLin-M-C3-DMA | [CAS]
1224606-06-7 | [Synonyms]
DLin-M-C3-DMA
D-LIN-MC3-DMA;DLINMC3DMA;D-LIN-MC-3-DMA;D-LIN-MC3-DMA
O-(Z,Z,Z,Z-heptatriaconta-6,9,26,29-tetraen-19-yl)-4-(N,N-dimethylamino)
(6Z,9Z,28Z,31Z)-heptatriacont-6,9,28,31-tetraene-19-yl 4-(dimethylamino)butanoate
(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate
Butanoic acid, 4-(dimethylamino)-, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecadien-1-yl ester | [Molecular Formula]
C43H79NO2 | [MDL Number]
MFCD31657426 | [MOL File]
1224606-06-7.mol | [Molecular Weight]
642.09 |
| Chemical Properties | Back Directory | [Boiling point ]
670.2±43.0 °C(Predicted) | [density ]
0.886±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
Soluble in Ethanol, DMSO, DMF | [form ]
Liquid | [pka]
9.37±0.28(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Description]
D-Lin-MC3-DMA (MC3, DLin-MC3-DMA,1224606-06-7) is a potent and ionizable cationic lipid. D-Lin-MC3-DMA is used for delivery of siRNA in vivo. DLin-MC3-DMA, or (6Z,9Z,28Z,31Z)-heptatriacont-6,9,28,31-tetraene-19-yl 4-(dimethylamino)butanoate , is one of the most utilized cationic lipids that is used for making Lipid Nano-Particles (LNPs). These lipids, can form nanoparticles that can encapsulate and deliver siRNA, mRNA, DNA or small molecules into the cytoplasm and represent the most advanced delivery platforms for systemic administration of active molecules.
| [Uses]
DLin-M-C3-DMA(1224606-06-7) is a commonly used drug delivery vehicle for the fabrication of lipid nanoparticles (LNPs), which exert therapeutic effects by encapsulating and delivering siRNA, mRNA, DNA, or small molecules into the cytoplasm of the cell, and is a potent siRNA delivery vehicle.
| [Biological Activity]
DLin-MC3-DMA(1224606-06-7) is an ionizable lipid used in combination with other lipids for encapsulation of RNA and DNA into lipid nanoparticles (LNPs). Administration of DLin-MC3-DMA based LNPs have delivered siRNA and reduced Factor VII levels in mice. Delivery of BCR-ABL siRNA reduced leukemic burden in a mouse model of chronic myeloid leukemia (CML).
| [storage]
Store at -20°C |
|
|